Millennium offer beats Genzyme's
618409
In a surprise attempt by a Cambridge biotechnology company to trump a takeover bid by one of its neighbors, Millennium Pharmaceuticals Inc. yesterday said it had reached a $515 million deal to buy a small Canadian drug firm that Genzyme Corp. has been trying to buy since late last month.
156850
Fifteen months ago, Genzyme Corp. and Transkaryotic Therapies Inc. of Cambridge decided to kiss and make up. It didn't last.
131156
LONDON (CBS.MW) -- The US Food and Drug Administration has approved a Genzyme Corp. (GENZ) cancer drug for treating a type of childhood leukemia after other therapies have failed.
238851
Genzyme Corp.  said on Friday  its osteoarthritis pain treatment Synvisc will retain a  separate, higher reimbursement rate, after the U.S. government  reversed its earlier decision to cut the rate, sending Genzyme  shares higher.
688289
The Food and Drug Administration approved Clolar, Genzyme Corp.'s new drug for patients under 21 with acute lymphocytic leukemia. An advisory panel on Dec. 1 recommended the drug be approved. Clolar was developed by Ilex Oncology Inc., the Texas firm Cambridge-based Genzyme acquired last week in a $1 billion stock transaction. The FDA panel recommended that more studies be done ...
198678
Biogen Idec and Irish drugmaker Elan Corp. won government approval yesterday to sell a new multiple sclerosis drug, Tysabri. The drug, which some analysts predict will bring in $2 billion
329681
Up 71% already from 2003-04 OGCbuying.solutions has provided a big increase in savings in the last two financial years, but could do even better according to a National Audit Office (NAO) reportâ¦
321630
Millennium Pharmaceuticals Inc. on  Monday said studies show that its drug Velcade is effective for  patients at all stages of the bone marrow cancer multiple  myeloma.
690464
Carl Icahn, the billionaire investor who recently helped put Biogen Idec Inc. in play, has taken a stake in another major Cambridge biotech - Genzyme Corp.
18221
Genzyme has agreed to pay at least $325 million to win the hotly contested rights to a potentially powerful cholesterol-lowering drug.
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
232342
Genzyme (GENZ :Nasdaq - news - research) shares rose early Wednesday after US regulators approved its leukemia drug for children. The Food and Drug Administration Tuesday approved the drug Clolar, an intravenous
725261
There's encouraging news about an enzyme replacement drug.
400715
Microbia Inc., a promising Cambridge biotech company, said it has signed a multimillion-dollar deal with a New York drug company to jointly develop and market Microbia's first drug.
763508
NEW YORK DEC 29, 2004  - Genzyme Corp. announced Wednesday that the US Food and Drug Administration (FDA) has approved the nucleoside analogue clofarabine (Clolar) for the treatment of children
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
336171
YESTERDAY Close $75.73 Change +$2.22 52-WEEK High $76.90 Low $58.71 Genzyme Corp. of Cambridge said profit jumped tenfold as sales increased for its medicines for rare genetic disorders, some of the world's costliest drugs. The company gained 3 percent in New York trading.